KRT-232 vs Ruxolitinib – MPN Research Foundation
Skip to content
Search for...
UNDERSTANDING MPNS
Primary Myelofibrosis (PMF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
Glossary
ABOUT MPNRF
Our Mission and History
Board of Directors
MPNRF Team
Scientific Advisory Board
Our Research Impact
Financials
Our Partners
Blog
LIVING WITH…
Find Support
Just Diagnosed
Patient’s Bill of Rights
MPN Clinical Trials
Patient Stories
MPN Community Calender
myMPN: Patient Registry for PV, ET AND MF
MPN News
Treatments
MAKE AN IMPACT
Make an Online Donation
Give in Memory
Join Team MPN
Estate Planning
Birthdays
RESEARCH
MPN Science Reports
Our Research Impact
MPNRF Annual Roundtable
myMPN History and Governance
Research We’re Funding Now
MPN Interferon Initiative
For Researchers
Apply For Grant
Button
Toggle Navigation
Toggle Navigation
UNDERSTANDING MPNS
Primary Myelofibrosis (PMF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
Glossary
ABOUT MPNRF
Our Mission and History
Board of Directors
MPNRF Team
Scientific Advisory Board
Our Research Impact
Financials
Our Partners
Blog
LIVING WITH…
Find Support
Just Diagnosed
Patient’s Bill of Rights
MPN Clinical Trials
Patient Stories
MPN Community Calender
myMPN: Patient Registry for PV, ET AND MF
MPN News
Treatments
MAKE AN IMPACT
Make an Online Donation
Give in Memory
Join Team MPN
Estate Planning
Birthdays
RESEARCH
MPN Science Reports
Our Research Impact
MPNRF Annual Roundtable
myMPN History and Governance
Research We’re Funding Now
MPN Interferon Initiative
For Researchers
Apply For Grant
KRT-232 vs Ruxolitinib
admin | March 11, 2021
